Actively Recruiting
Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies
Led by National University Hospital, Singapore · Updated on 2025-07-25
37
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
Sponsors
N
National University Hospital, Singapore
Lead Sponsor
N
National University of Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
DRUID is a treatment decision support tool combining predictive models and public databases related to multi-gene markers, drug response screens, gene essentiality and clinical status of drugs to provide drug recommendations personalized based on an input genomic profile. We hypothesize that DRUID analysis of patients' somatic mutational profile from NGS diagnostic platform can be used as a treatment decision support tool in patients with refractory cancer without targetable mutations.
CONDITIONS
Official Title
Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years or older
- Histological or cytological diagnosis of solid organ malignancy
- Available comprehensive NGS panel test results from tumor tissue or blood-based assay performed in metastatic setting
- ECOG performance status of 0 to 2
- At least one measurable tumor lesion based on RECIST 1.1 criteria
- Estimated life expectancy of at least 12 weeks
- Documented progressive disease from last line of therapy
- Received at least two lines of palliative systemic therapy with no standard therapy available
- Adequate organ function including: absolute neutrophil count 1.5 x 10^9/L, platelets 100 x 10^9/L, hemoglobin 8 x 10^9/L
- Hepatic function with bilirubin 1.5 x ULN, ALT or AST 2.5x ULN (or 5x ULN with liver metastases)
- Renal function with creatinine 1.5x ULN
- Signed informed consent from patient or legal representative
- Ability to comply with study procedures
You will not qualify if you...
- Treatment with any investigational drug within the last 30 days
- Concurrent use of other tumor therapies including chemotherapy, hormonal therapy, or immunotherapy
- Major surgery within 28 days before study drug administration
- Active infection compromising ability to tolerate therapy
- Pregnancy
- Breastfeeding
- Serious disorders compromising safety or study completion
- Active bleeding disorder or bleeding site
- Non-healing wound
- Clinically detectable second primary malignancy at enrollment
- Symptomatic brain metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematology-Oncology, National University Hospital
Singapore, Singapore, 119074
Actively Recruiting
Research Team
R
Robert John Walsh
CONTACT
R
Robert John Walsh
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here